Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)---- $ALT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT). Investors who purchased Altimmune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALT. Investigation Details: Altimmune's stock price has more than tripled since November, after the Company reported that data.

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

ProShares Ultra Nasdaq Biotechnology

Pyxis Oncology

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

NEW YORK--(BUSINESS WIRE)---- $ALT #ALT--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

Altimmune (NASDAQ: ALT) share price experienced a significant decline on Tuesday following a report by Kerrisdale Capital, in which the investment firm disclosed a short position in the company's shares. Kerrisdale's critical analysis suggests that Altimmune's pharmaceutical endeavors may be fraught with challenges, dampening investor confidence and contributing to a bearish sentiment surrounding the stock.

Altimmune stock tanks on report, should you buy the dip?

Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ: ALT ). The acclaimed short seller has just released a damning short report on the company, saying that its only viable product, a weight-loss drug, has little chance of commercial success and will “bomb” in upcoming Phase 3 trials.

Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report

Shares of obesity drug developer Altimmune fell 10% to $9.36 on Tuesday, after Kerrisdale Capital took a short position on the company's stock.

Altimmune shares slide after Kerrisdale Capital takes short position

Amgen

Biohaven Pharmaceutical Hld

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Agnico Eagle Mines

Alamos Gold

Apollo Global Management

Arcos Dorados Hlds

Alexandria Real Estate Equities

Academy Sports and Outdoors

AeroVironment

Alphabet

Alpine Income Property Trust

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 1 of this series includes Academy Sports and Outdoors, Agnico Eagle Mines, Alphabet, Altimmune, and Arista Networks, among others.

MoneyShow's Best Investment Ideas For 2024: Part 1

The Altimmune (NASDAQ: ALT) stock price has been in a strong uptrend in the past few months. It bottomed at $2.07 in October, and the shares have surged by over 475% to its highest level since February.

Up for 8 straight weeks, is Altimmune (ALT) stock a good buy?

Altimmune's weight loss drug, Pemvidutide, showed promising results in a phase 2 trial, with a mean weight loss of 15.6% at week 48. The drug also demonstrated better CV risk reduction, lipid changes and tolerability than its competitors, semaglutide and tirzepatide. Altimmune's stock is undervalued compared to the potential market success of a weight loss drug, with potential for significant upside.

Thoroughly Derisked, Altimmune Is Now A Great Buy

Omega Therapeutics

Viking Therapeutics

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.

The 3 Best Biotech Stocks to Buy in January 2024

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH2. Details for the presentation are as follows:

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

Eli Lilly

Novo Nordisk

Structure Therapeutics Inc

Roche Holding AG

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

The runaway success of weight-loss drugs like Novo Nordisk A/S NYSE: NVO Ozempic and Eli Lilly and Co. NYSE: LLY Mounjaro has kicked off a gold rush for new weight-loss drugs in the medical sector. One of the major complaints about glucagon-like peptide-1 (GLP-1) drugs is the nausea and vomiting that comes with the usage of these drugs.

Can Altimmune's weight-loss drug be a game-changer?

Altimmune (NASDAQ: ALT) stock proce has staged a strong recovery in the past few days, making it one of the most popular companies among day traders. The shares jumped to a high of $8.63 on Thursday, about 306% above the lowest point this year, giving it a market cap of over $353 million.

Is Altimmune (ALT) stock a good buy after the 306% jump?

Options traders are targeting Altimmune Inc (NASDAQ:ALT), as the stock shoots for its 11th-straight win.

Call Traders Targeting Rallying Weight-Loss Drug Developer

Altimmune Inc. shares ALT, +1.02% gained 5% Thursday and have jumped more than 100% this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.

Altimmune shares pop as analysts see obesity-drug partnership potential

Positive results were achieved from the 48-week phase 2 MOMENTUM study using pemvidutide for the treatment of patients with obesity. The highest dose of 2.4 mg of pemvidutide achieved 15.6% weight loss for obese patients. Altimmune has two other upcoming catalysts: phase 2 study results for Hepatitis B treatment in Q1 2024 and phase 2b IMPACT trial results for NASH treatment in Q1 2025.

Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook

NEW YORK, NY, December 05, 2023 – PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Altimmune, Inc. (Nasdaq: ALT) which has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The company's study enrolled 391 subjects with obesity and at least one comorbidity.

PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE'S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL

Weight-loss drug developer Altimmune is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg told Reuters on Tuesday.

Altimmune open to partnerships, deals with drugmakers, says CEO

Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.

Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study

Altimmune (NASDAQ: ALT ) stock is rising higher on Friday after the company posted positive results from a weight loss drug trial. Those results come from the biopharmaceutical company's Phase 2 obesity trial of pemvidutide.

Why Is Altimmune (ALT) Stock Up 43% Today?

Green Giant Inc

Harbor Custom Development, Inc.

NexImmune

Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.

Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping

Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks Robust reductions in BMI and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate Altimmune to host conference call tomorrow at 8:30 am EST GAITHERSBURG, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.

News for Altimmune Stock (ALT)